1. Generics Bulletin

Teva Settles With Pfizer Over Xeljanz XR As 2025 Date Looms

Israeli Firm Previously Sued Over Patent Expiring In 2034

 
• By Dean Rudge

Teva has opted against litigating with Pfizer over its controversial Xeljanz XR JAK inhibitor, settling patent infringement proceedings over a US patent scheduled to expire in 2034. Zydus Cadila recently bagged 180 days of exclusivity for a strength of its ANDA product.

women's handshake
Teva was sued by Pfizer at the end of 2018 • Source: Alamy

Teva Pharmaceutical Industries Ltd. has agreed to settle and dismiss US patent litigation with Pfizer over intellectual property shielding the originator’s Xeljanz XR (tofacitinib) 11mg extended-release tablets blockbuster treatment for autoimmune diseases.

According to a stipulation of dismissal filed in a Delaware district court, Pfizer – along with several of its subsidiaries – and Teva Pharmaceutical USA agreed that “all claims and counterclaims between plaintiffs and defendant are dismissed without prejudice

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.